Skip to content

Press Releases and Events

Press Releases

Filter Releases
Press Releases and Events
Date Title and Summary View
Jun 21, 2007
NEW YORK, NY, JUNE 21, 2007 -- Intra-Cellular Therapies, Inc., today announced it has initiated Phase I clinical trials for ITI-007, the Company's first-in-class dual 5HT2A receptor antagonist/dopamine receptor phosphoprotein modulator (DPPM) for the treatment of schizophrenia, and ITI-722, a low dose formulation of ITI-007 with selective 5HT2A ...
Jun 1, 2005
Intra-Cellular Therapies, Inc., (ITI) a privately held biopharmaceutical company focusing on the development of new therapeutics for neuropsychiatric and neurodegenerative disorders, today announced that it has been granted an exclusive, worldwide license to a family of pre-clinical compounds from Bristol-Myers Squibb Company (NYSE: BMY). ...
Page: First Previous
= add release to Briefcase

Upcoming Events

Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.